PE20030129A1 - Imidazotriazinas - Google Patents

Imidazotriazinas

Info

Publication number
PE20030129A1
PE20030129A1 PE2002000536A PE2002000536A PE20030129A1 PE 20030129 A1 PE20030129 A1 PE 20030129A1 PE 2002000536 A PE2002000536 A PE 2002000536A PE 2002000536 A PE2002000536 A PE 2002000536A PE 20030129 A1 PE20030129 A1 PE 20030129A1
Authority
PE
Peru
Prior art keywords
triazin
imidazo
dimethyl
amine
aryl
Prior art date
Application number
PE2002000536A
Other languages
English (en)
Inventor
Marcus Bauser
Adrian Tersteegen
Nils Burkhardt
Jens-Kerim Erguden
Dietmar Flubacher
Arno Friedl
Irene Gerlach
Martin Hendrix
Volker Hinz
Reinhard Jork
Paul Naab
Ulrich Niewohner
Thorsten-Oliver Repp
Dagmar Schaus
Karl-Heinz Schlemmer
Juergen Stoltefus
David Bruckner
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PE20030129A1 publication Critical patent/PE20030129A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A IMIDAZOTRIAZINAS DE FORMULA I DONDE R1 ES ARILO C6-C10 CON HALOGENO, FORMILO, CARBAMOILO, -SO2NR5R6 DONDE R5 Y R6 SON H, ALQUILO C1-C6; R2 ES UN RESTO HIDROCARBURO DE 1 A 10 ATOMOS DE CARBONO; R3 ES METILO, ETILO; R7 ES H, ALQUILO C1-C6 CON ALCOXI C1-C3; E ES UN ENLACE O ALCANODIILO C1-C3; R4 ES ARILO C6-C10, HETEROARILO DE 5 A 10 MIEMBROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION Y COMPUESTOS INTERMEDIOS. SON COMPUESTOS PREFERIDOS 2-(3,4-DIMETOXIFENIL)-5,7-DIMETIL-N-(3,4,5-TRIMETOXIFENIL)IMIDAZO[5,1-f][1,2,4]TRIAZIN-4-AMINA, 2-(3,4-DIMETOXIFENIL)-5,7-DIMETIL-4-[(2-METIL-3-FURIL)SULFANIL]IMIDAZO[5,1-f][1,2,4]TRIAZIN-4-AMINA, N-(3,5-DIMETOXIBENCIL)-2-(3,4-DIMETOXIFENIL)-5,7-DIMETIL-IMIDAZO[5,1-f][1,2,4]TRIAZIN-4-AMINA, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS COMO PARKINSON
PE2002000536A 2001-06-22 2002-06-21 Imidazotriazinas PE20030129A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10130167A DE10130167A1 (de) 2001-06-22 2001-06-22 Imidazotriazine

Publications (1)

Publication Number Publication Date
PE20030129A1 true PE20030129A1 (es) 2003-03-13

Family

ID=7689090

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000536A PE20030129A1 (es) 2001-06-22 2002-06-21 Imidazotriazinas

Country Status (11)

Country Link
US (1) US6936609B2 (es)
EP (1) EP1404677A1 (es)
JP (1) JP2004534827A (es)
AR (1) AR036103A1 (es)
CA (1) CA2451525A1 (es)
DE (1) DE10130167A1 (es)
DO (1) DOP2002000429A (es)
GT (1) GT200200122A (es)
PE (1) PE20030129A1 (es)
SV (1) SV2003001107A (es)
WO (1) WO2003000693A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
MX2009010450A (es) 2007-03-27 2009-11-23 Omeros Corp El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
DE102008035209A1 (de) 2008-07-29 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102007060172A1 (de) 2007-12-13 2009-06-25 Bayer Healthcare Ag Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102008023801A1 (de) * 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
KR101324329B1 (ko) * 2008-09-04 2013-10-31 미쓰비시 타나베 파마 코퍼레이션 삼치환된 피리미딘 화합물 및 ｐｄｅ10 억제제로서의 그의 용도
WO2010030027A1 (en) 2008-09-10 2010-03-18 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
PH12012501643A1 (en) * 2010-02-26 2017-07-19 Mitsubishi Tanabe Pharma Corp Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
US20130071415A1 (en) * 2010-05-28 2013-03-21 Biocryst Pharmaceuticals, Inc. Heterocyclic Compounds as Janus Kinase Inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR102385359B1 (ko) 2010-11-08 2022-04-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
JP5543039B2 (ja) 2011-02-23 2014-07-09 ファイザー・インク 神経障害治療のためのイミダゾ［５，１−ｆ］［１，２，４］トリアジン
JP2014231475A (ja) * 2011-08-25 2014-12-11 田辺三菱製薬株式会社 新規化合物及びそのｐｄｅ１０阻害薬としての使用
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
TR201904614T4 (en) 2013-02-27 2019-05-21 Mochida Pharm Co Ltd Novel pyrazole derivative.
MD20150103A2 (ro) 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
CA3264513A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh USE OF SUBSTITUTED BENZOFURAN AND BENZOXAZOLE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERCISE INTOLERANCE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
HU227841B1 (en) * 1997-11-12 2012-05-02 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
AU7766300A (en) * 1999-10-07 2001-05-10 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulatingsame

Also Published As

Publication number Publication date
US20040249148A1 (en) 2004-12-09
WO2003000693A1 (de) 2003-01-03
DE10130167A1 (de) 2003-01-02
EP1404677A1 (de) 2004-04-07
GT200200122A (es) 2003-06-05
SV2003001107A (es) 2003-03-18
CA2451525A1 (en) 2003-01-03
AR036103A1 (es) 2004-08-11
US6936609B2 (en) 2005-08-30
JP2004534827A (ja) 2004-11-18
DOP2002000429A (es) 2003-10-15

Similar Documents

Publication Publication Date Title
PE20211795A1 (es) Compuestos heteroaril tetraciclicos
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
PE20050774A1 (es) Pirazolopirimidinas como inhibidores de quinasa ciclina-dependientes
PE20030292A1 (es) Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gabaa
PE20030155A1 (es) Azaindoles como inhibidores de quinasas
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
AR072756A2 (es) Intermediarios para la preparacion; derivados de triazolo[4,5-d]pirimidina, utiles como antitromboticos
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
CY1109263T1 (el) Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine
PE20020406A1 (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6-DISUSTITUIDAS COMO INHIBIDORES DE LAS PROTEINAS CINASAS
UY25344A1 (es) Procedimiento para la preparacion de derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
ATE443063T1 (de) Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
PE20010629A1 (es) Derivados de triazolpiridinamina como ligandos de receptores de adenosina
AR007828A1 (es) Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos
EA200400236A1 (ru) Производные замещенного 2-пиримидинил-6,7,8,9-тетрагидропиримидо[1,2-a]пиримидин-4-она и 7-пиримидинил-2,3-дигидроимидазо[1,2-a]пиримидин-5(1h)она для нейродегенеративных нарушений
PE20010638A1 (es) Imidazo-5-il-aminas biciclicas, medicamentos que las contienen, su uso para la preparacion de medicamentos y procedimiento para su preparacion
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
ATE348101T1 (de) Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion
AR033753A1 (es) Derivados de imidazo[1,5-a]pirimido[5,4-d]benzazepina
DE602004011330D1 (de) Imidazo- und thiazolopyridine als jak3-kinase-inhibitoren
RU2012128551A (ru) Производные этинила
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20100741A1 (es) COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
NO20080418L (no) Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme

Legal Events

Date Code Title Description
FC Refusal